KNSA(Kiniksa Pharmaceuticals International, plc) · 财务报表

KNSA(Kiniksa Pharmaceuticals International, plc) 的财务报表:医疗保健,特药与仿制药。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2021-12-31FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$38.54M$220.18M$270.26M$423.24M$677.56M
毛利润$29.44M$197.28M$236.85M$362.33M$599.89M
营业利润−$156.64M$9.77M−$25.20M−$45.62M$77.22M
净利润−$157.92M$183.36M$14.08M−$43.19M$59.01M
经营现金流−$126.30M$5.81M$13.30M$25.69M$137.99M
自由现金流−$126.71M$5.70M$13.17M$25.41M$136.42M
摊薄每股收益$-2.30$2.60$0.20$-0.60$0.75

Kiniksa Pharmaceuticals International, plc KNSA